Blivet-Van Eggelpoël et al. provided evidence that dysregulation of the EGFR/HER-3 signaling pathway limits the efficacy of sorafenib in treatment-naïve or acquired-resistant HCC cells. This evidence concerns the gene EGFR and hepatocellular carcinoma.